Aducanumab Not Recommended by FDA, White Paper on Mechanical Thrombectomy, Status Epilepticus Treatment FDA Approved
Neurology News Network for the week ending November 14, 2020.
This week Neurology News Network covered the FDA's Peripheral and Central Nervous System Drugs Advisory Committee decision to not recommend aducanumab for the treatment of Alzheimer disease, a white paper published which called for an increased use of mechanical thrombectomy, and the FDA approval of fosphenytoin sodium for injection for patients with status epilepticus.
Welcome to this special edition of Neurology News Network. I’m Marco Meglio. Please excuse our appearance this week as a majority of the US workforce, including the NeurologyLive team, moves to working remote as we come together to help reduce the spread of the novel coronavirus.
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee
A
The FDA has approved fosphenytoin sodium for injection (Sesquient) from Sedor Pharmaceuticals for treatment of status epilepticus (SE) in adults and children.Currently, the injectable is the only room temperature-stable fosphenytoin approved for treatment of SE. Cerebryx is another fosphenytoin currently used to treat SE, but it requires refrigerated storage in the pharmacy which can create a delay between symptom onset and treatment. Neurocritical Care Society guidelines state that irreversible brain damage or death may occur if seizures are not stopped within 60 minutes of onset. The treatment allows for point-of-care storage and administration in first responder vehicles, emergency rooms, long-term care facilities, and others critical areas where prompt care is needed.
For more direct access to expert insight, head to NeurologyLive.com. This has been Neurology News Network. Thanks for watching.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.